Interestingly, Triozzi et al. (2022), by evaluating the bioenergetics of circulating immune cells as well as the MS-measured serum metabolomic profile in samples collected at baseline from 40 melanoma patients treated with anti-PD1 therapy, suggested that a glycolytic signature is associated with checkpoint inhibitor responders [25]. This evidence concerns the gene PDCD1 and melanoma.